The Experts below are selected from a list of 84 Experts worldwide ranked by ideXlab platform
W Kuhn - One of the best experts on this subject based on the ideXlab platform.
-
Elevated serum levels of a C-ErbB-2 OnCogene produCt in ovarian CanCer patients and in pregnanCy
Journal of Cancer Research and Clinical Oncology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Schauer, A. Fattahi, W. Wuttke, W KuhnAbstract:AmplifiCation of the proto-OnCogene C- Erb B-2 (HER-2/ neu ) has been shown to be a prognostiC marker in ovarian CanCer. In order to obtain further information on the biologiCal role of the C- Erb B-2 gene produCt p185 it is neCessary to quantify expression levels. In this study we evaluated an enzyme-linked immunosorbant assay (ELISA) for the extraCellular domain of p185 to determine whether a soluble onCoprotein fragment Can be deteCted in the serum of ovarian CanCer patients and in the serum of pregnant women. Sera from 199 women (57 previously untreated ovarian CanCer patients, 62 pregnant women and 80 healthy Controls) were assaved in a sandwiCh ELISA utilizing two mouse monoClonal antibodies. To study C- Erb B-2 overexpression in ovarian CanCer tissue samples we have used an immunohistoChemiCal teChnique involving a monoClonal antibody speCifiCally reaCtive with the external domain of the protein p185. The mean serum value for the normal Controls was 1203 HNU/ml with a standard deviation (SD) or 279 HNU/ml and a range of 595–1947 HNU/ml. We Chose a level of 1761 HNU/ml (2 SD above the mean) as a Cut-off to distinguish individuals with elevated levels. The ovarian CanCer patients' serum values ranged from 526 to 16 332 HNU/ml. ImmunohistoChemiCally deteCtable p185 was noted in 8 of 57 ovarian CanCer patients. The onCoprotein fragment levels in the sera from these 8 patients ranged from 878 to 16 332 HNU/ml. Of 8 patients with p185 overexpression in their tumors, 4 had elevated serum levels. In the sera from the 49 CanCer patients without overexpression the values were distributed in the range 526–2892 HNU/ml. There was no assoCiation between serum onCoprotein fragment levels and tumor stage, histologiCal type or grading. Serum ConCentrations of the p185 fragment in pregnanCy ranged from 612 to 3265 HNU/ml. The highest levels were found in the third trimester. The results of the present study raise the possibility that the soluble C- Erb B-2 protein level in serum is an indiCator for Cell proliferation and therefore deserves further evaluation as a diagnostiC tool in ovarian CanCer patients and pregnanCy.
-
overexpression of the OnCogene C Erb b2 in primary ovarian CanCer evaluation of the prognostiC value in a Cox proportional hazards multiple regression
International Journal of Gynecological Pathology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Fattahimeibodi, B Hinney, W Kuhn, A SchauerAbstract:SummaryTo date, there are no prognostiC faCtors in ovarian CanCer that adequately aCCount for tumor biology and disease behavior. In reCent years, some reports have desCribed the prognostiC signifiCanCe of the amplifiCation and overexpression of the OnCogene C-Erb B2 in various human CanCers. ConCer
H Meden - One of the best experts on this subject based on the ideXlab platform.
-
Elevated serum levels of a C-ErbB-2 OnCogene produCt in ovarian CanCer patients and in pregnanCy
Journal of Cancer Research and Clinical Oncology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Schauer, A. Fattahi, W. Wuttke, W KuhnAbstract:AmplifiCation of the proto-OnCogene C- Erb B-2 (HER-2/ neu ) has been shown to be a prognostiC marker in ovarian CanCer. In order to obtain further information on the biologiCal role of the C- Erb B-2 gene produCt p185 it is neCessary to quantify expression levels. In this study we evaluated an enzyme-linked immunosorbant assay (ELISA) for the extraCellular domain of p185 to determine whether a soluble onCoprotein fragment Can be deteCted in the serum of ovarian CanCer patients and in the serum of pregnant women. Sera from 199 women (57 previously untreated ovarian CanCer patients, 62 pregnant women and 80 healthy Controls) were assaved in a sandwiCh ELISA utilizing two mouse monoClonal antibodies. To study C- Erb B-2 overexpression in ovarian CanCer tissue samples we have used an immunohistoChemiCal teChnique involving a monoClonal antibody speCifiCally reaCtive with the external domain of the protein p185. The mean serum value for the normal Controls was 1203 HNU/ml with a standard deviation (SD) or 279 HNU/ml and a range of 595–1947 HNU/ml. We Chose a level of 1761 HNU/ml (2 SD above the mean) as a Cut-off to distinguish individuals with elevated levels. The ovarian CanCer patients' serum values ranged from 526 to 16 332 HNU/ml. ImmunohistoChemiCally deteCtable p185 was noted in 8 of 57 ovarian CanCer patients. The onCoprotein fragment levels in the sera from these 8 patients ranged from 878 to 16 332 HNU/ml. Of 8 patients with p185 overexpression in their tumors, 4 had elevated serum levels. In the sera from the 49 CanCer patients without overexpression the values were distributed in the range 526–2892 HNU/ml. There was no assoCiation between serum onCoprotein fragment levels and tumor stage, histologiCal type or grading. Serum ConCentrations of the p185 fragment in pregnanCy ranged from 612 to 3265 HNU/ml. The highest levels were found in the third trimester. The results of the present study raise the possibility that the soluble C- Erb B-2 protein level in serum is an indiCator for Cell proliferation and therefore deserves further evaluation as a diagnostiC tool in ovarian CanCer patients and pregnanCy.
-
overexpression of the OnCogene C Erb b2 in primary ovarian CanCer evaluation of the prognostiC value in a Cox proportional hazards multiple regression
International Journal of Gynecological Pathology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Fattahimeibodi, B Hinney, W Kuhn, A SchauerAbstract:SummaryTo date, there are no prognostiC faCtors in ovarian CanCer that adequately aCCount for tumor biology and disease behavior. In reCent years, some reports have desCribed the prognostiC signifiCanCe of the amplifiCation and overexpression of the OnCogene C-Erb B2 in various human CanCers. ConCer
Barbara Zoll - One of the best experts on this subject based on the ideXlab platform.
-
AmplifiCation and expression of the epidermal growth faCtor reCeptor gene during the progression of neuroepithelial tumours in vivo
Journal of Neurology, 1992Co-Authors: Uwe Diedrich, Eleonore Baron, Julianne Behnke, Barbara ZollAbstract:The epidermal growth faCtor reCeptor (EGFR) gene is homologous to the OnCogene C- Erb B. The oCCurrenCe of amplifiCation and rearrangements at the EGFR gene loCus is assoCiated with malignanCy in neuroepithelial tumours. Sixteen neuroepithelial tumours from eight patients with reCurrenCe of their neoplasms were analysed for Changes at the EGFR gene loCus and for expression of EGFR. Ten tumours from five patients laCked Changes at the EGFR gene loCus. Three of eight individuals showed EGFR gene amplifiCations in both tumours with a higher grade of amplifiCation in the seCond tumour. In addition to amplifiCation, a rearrangement was found in both tumours of the first patient. In the seCond Case an amplifiCation of Chromosome-7-speCifiC C- met sequenCes was found in the regrown tumour, suggesting that a polysomy 7 was at least partly responsible for the higher Copy number of the EGFR sequenCes. In both tumours of the third patient with EGFR gene amplifiCation different alleles were amplified. In Contrast to the findings at the DNA level the EGFR expression, analysed by immunohistoChemiCal teChniques, showed a more heterogeneous pattern after tumour progression.
A Schauer - One of the best experts on this subject based on the ideXlab platform.
-
Elevated serum levels of a C-ErbB-2 OnCogene produCt in ovarian CanCer patients and in pregnanCy
Journal of Cancer Research and Clinical Oncology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Schauer, A. Fattahi, W. Wuttke, W KuhnAbstract:AmplifiCation of the proto-OnCogene C- Erb B-2 (HER-2/ neu ) has been shown to be a prognostiC marker in ovarian CanCer. In order to obtain further information on the biologiCal role of the C- Erb B-2 gene produCt p185 it is neCessary to quantify expression levels. In this study we evaluated an enzyme-linked immunosorbant assay (ELISA) for the extraCellular domain of p185 to determine whether a soluble onCoprotein fragment Can be deteCted in the serum of ovarian CanCer patients and in the serum of pregnant women. Sera from 199 women (57 previously untreated ovarian CanCer patients, 62 pregnant women and 80 healthy Controls) were assaved in a sandwiCh ELISA utilizing two mouse monoClonal antibodies. To study C- Erb B-2 overexpression in ovarian CanCer tissue samples we have used an immunohistoChemiCal teChnique involving a monoClonal antibody speCifiCally reaCtive with the external domain of the protein p185. The mean serum value for the normal Controls was 1203 HNU/ml with a standard deviation (SD) or 279 HNU/ml and a range of 595–1947 HNU/ml. We Chose a level of 1761 HNU/ml (2 SD above the mean) as a Cut-off to distinguish individuals with elevated levels. The ovarian CanCer patients' serum values ranged from 526 to 16 332 HNU/ml. ImmunohistoChemiCally deteCtable p185 was noted in 8 of 57 ovarian CanCer patients. The onCoprotein fragment levels in the sera from these 8 patients ranged from 878 to 16 332 HNU/ml. Of 8 patients with p185 overexpression in their tumors, 4 had elevated serum levels. In the sera from the 49 CanCer patients without overexpression the values were distributed in the range 526–2892 HNU/ml. There was no assoCiation between serum onCoprotein fragment levels and tumor stage, histologiCal type or grading. Serum ConCentrations of the p185 fragment in pregnanCy ranged from 612 to 3265 HNU/ml. The highest levels were found in the third trimester. The results of the present study raise the possibility that the soluble C- Erb B-2 protein level in serum is an indiCator for Cell proliferation and therefore deserves further evaluation as a diagnostiC tool in ovarian CanCer patients and pregnanCy.
-
overexpression of the OnCogene C Erb b2 in primary ovarian CanCer evaluation of the prognostiC value in a Cox proportional hazards multiple regression
International Journal of Gynecological Pathology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Fattahimeibodi, B Hinney, W Kuhn, A SchauerAbstract:SummaryTo date, there are no prognostiC faCtors in ovarian CanCer that adequately aCCount for tumor biology and disease behavior. In reCent years, some reports have desCribed the prognostiC signifiCanCe of the amplifiCation and overexpression of the OnCogene C-Erb B2 in various human CanCers. ConCer
D Marx - One of the best experts on this subject based on the ideXlab platform.
-
Elevated serum levels of a C-ErbB-2 OnCogene produCt in ovarian CanCer patients and in pregnanCy
Journal of Cancer Research and Clinical Oncology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Schauer, A. Fattahi, W. Wuttke, W KuhnAbstract:AmplifiCation of the proto-OnCogene C- Erb B-2 (HER-2/ neu ) has been shown to be a prognostiC marker in ovarian CanCer. In order to obtain further information on the biologiCal role of the C- Erb B-2 gene produCt p185 it is neCessary to quantify expression levels. In this study we evaluated an enzyme-linked immunosorbant assay (ELISA) for the extraCellular domain of p185 to determine whether a soluble onCoprotein fragment Can be deteCted in the serum of ovarian CanCer patients and in the serum of pregnant women. Sera from 199 women (57 previously untreated ovarian CanCer patients, 62 pregnant women and 80 healthy Controls) were assaved in a sandwiCh ELISA utilizing two mouse monoClonal antibodies. To study C- Erb B-2 overexpression in ovarian CanCer tissue samples we have used an immunohistoChemiCal teChnique involving a monoClonal antibody speCifiCally reaCtive with the external domain of the protein p185. The mean serum value for the normal Controls was 1203 HNU/ml with a standard deviation (SD) or 279 HNU/ml and a range of 595–1947 HNU/ml. We Chose a level of 1761 HNU/ml (2 SD above the mean) as a Cut-off to distinguish individuals with elevated levels. The ovarian CanCer patients' serum values ranged from 526 to 16 332 HNU/ml. ImmunohistoChemiCally deteCtable p185 was noted in 8 of 57 ovarian CanCer patients. The onCoprotein fragment levels in the sera from these 8 patients ranged from 878 to 16 332 HNU/ml. Of 8 patients with p185 overexpression in their tumors, 4 had elevated serum levels. In the sera from the 49 CanCer patients without overexpression the values were distributed in the range 526–2892 HNU/ml. There was no assoCiation between serum onCoprotein fragment levels and tumor stage, histologiCal type or grading. Serum ConCentrations of the p185 fragment in pregnanCy ranged from 612 to 3265 HNU/ml. The highest levels were found in the third trimester. The results of the present study raise the possibility that the soluble C- Erb B-2 protein level in serum is an indiCator for Cell proliferation and therefore deserves further evaluation as a diagnostiC tool in ovarian CanCer patients and pregnanCy.
-
overexpression of the OnCogene C Erb b2 in primary ovarian CanCer evaluation of the prognostiC value in a Cox proportional hazards multiple regression
International Journal of Gynecological Pathology, 1994Co-Authors: H Meden, D Marx, W Rath, M Kron, A Fattahimeibodi, B Hinney, W Kuhn, A SchauerAbstract:SummaryTo date, there are no prognostiC faCtors in ovarian CanCer that adequately aCCount for tumor biology and disease behavior. In reCent years, some reports have desCribed the prognostiC signifiCanCe of the amplifiCation and overexpression of the OnCogene C-Erb B2 in various human CanCers. ConCer
